TTC17 and breast cancer: Considering that paclitaxel is usually administered as a single agent or in combination in (neo)adjuvant and salvage chemotherapy against BC, making it the mainstay of therapeutic regimens, TTC17 expression could be used to identify patients who respond better to paclitaxel in clinical practice.